藥物治療是子宮內(nèi)膜癌治療的重要組成部分，常用藥物包括激素治療藥物（孕激素、抗雌激素藥物、促性腺激素釋放激素激動劑）、化療藥物（紫杉醇、鉑類、蒽環(huán)類）和靶向藥物（表皮生長因子受體拮抗劑、哺乳動物雷帕霉素靶蛋白抑制劑等）。隨著研究的深入，越來越多的抗子宮內(nèi)膜癌新靶點被發(fā)現(xiàn)，包括血管內(nèi)皮生長因子（VEGF）、聚腺苷二磷酸核糖聚合酶（PARP）、程序性死亡受體1（PD-1）和PD-1配體（PD-L1），中藥和天然單體化合物也是目前的研究熱點。對子宮內(nèi)膜癌治療藥物的作用機制及研究進(jìn)展進(jìn)行綜述，以期對該病治療及新藥研發(fā)有所裨益。

Drug therapy is an important part of endometrial cancer (EC) treatment. Commonly used clinical drugs include hormone therapy drugs (progestins, anti-estrogen drugs, gonadotropin releasing hormone agonists), chemotherapy drugs (paclitaxel, platinum Drugs, anthracyclines) and targeted drugs (epidermal growth factor receptor antagonists, mammalian target of rapamycin inhibitors, etc.). With the in-depth study of the mechanism, more and more new anti-EC targets have been discovered, including vascular endothelial growth factor (VEGF), polyadenosine diphosphate ribose polymerase (PARP), programmed death receptor 1 (PD-1) and PD-1 ligand (PD-L1). At the same time, the treatment of EC with traditional Chinese medicine and natural monomer compounds is also a hot spot of current research. The mechanism of action of EC drugs and the research progress are summarized, hoping to be beneficial to the treatment and new drug development of EC.

R979.1;R965